INC Research named David Subich as senior director, clinical operations for metabolic and endocrine diseases. He was formerly a professor at Ohio State. “Subich has a unique combination of research experience and hands-on medical practice in a variety of environments. He has witnessed the rise of metabolic diseases as a physician and understands the benefits of developing safe and effective drugs to treat patients,” said John Potthoff, COO of INC Research. Here’s the release.

PPD named Christine Dingivan executive VP and chief medical officer. She spent 12 years at MedImmune. Separately, PPD reported revenue growth of 16 percent, to $407 million. “We believe the market for CRO services is strong, even though our new authorizations came in lower than expected for the quarter,” CEO Fred Eshelman said in a statement. “Request-for-proposal volume remains high, and we will continue to focus our efforts on operational excellence and sales execution.” Here’s a story.

Phlexglobal is branching out to serve the health care sector. Phlexglobal’s Sarah Tucker says: “We have completed a number of successful projects within the National Health Service and are looking to build upon that success and develop the working model further across the sector.” Here’s the release.

GVK Biosciences, an Asian CRO, announced the appointment of Tarun Khanna to its board of directors. Tarun Khanna is a professor at Harvard. “Tarun’s vast experience in global strategy and understanding of the emerging markets will facilitate GVK to grow to the next level,” said D.S. Brar, chairman, GVK Biosciences. Here’s the release.

ClinicAid Research Management and Quartesian announced the formation of a joint venture to be called Clinesian. “ClinicAid and Quartesian have both benefited from a strong relationship over the past year, and this agreement is a natural extension of that relationship,” said Gary Slizgi, CEO.  Here’s the release.

Acurian, a provider of patient recruitment solutions, announced its opt-in database of self-reported chronic disease sufferers has more than 50 million patients. It has extended by five years its exclusive agreement with the largest aggregator of self-reported ailment data. “The growth of our patient database mirrors that of our business,” said Rick Malcolm, Acurian’s CEO. “In the past two years, we’ve seen our patient recruitment projects increase significantly as customers have requested more randomizations for larger studies consisting of multiple protocols across hundreds of sites.” Here’s the release.

Have a news release? Send it to .